CSF1R and neoplasm: In a study using an aggressive transgenic mouse model of mammary adenocarcinoma development [MMTV–polyoma middle T (PyMT) mice (63)], combination of CSF1R-signaling antagonists that block infiltration of mammary tumors by CD68+ macrophages, in combination with Paclitaxel, improved survival, delayed primary tumor growth and reduced pulmonary metastasis.